TICKERNERD
Menu
TLRYTLRYHealthcare · Drug Manufacturers - Specialty & Generic

TLRY Stock Forecast: Tilray Brands, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$3.14
−3.98% on the day

The 10 Wall Street analysts covering Tilray Brands, Inc. hold a median 12-month price target of $4.5 — +43.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 14 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$483.3M
Ticker Nerd rank
16 / 100
Median analyst target
$4.50
Analysts covering
10
Revenue$281.7M+25.5% y/y
Operating income−$4.5M
Net income−$37.9M
Free cash flow−$47.5M
Quarterly, 8 quarters to 31 May 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.6%
1M
−24.2%
YTD
−65.2%
1Y
−80.4%
From 52W high
−81.3%
From 52W low
0.0%
$3
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TLRY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tilray Brands, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
16 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
95
Size
53
Revisions
37
Accruals
33
Quality
24
Value
23
Issuance
17
Volatility
15
Momentum
6

Growth (95): Sales and profits are climbing, and climbing faster than before.

Momentum (6): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TLRY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TLRY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15Jan 26Apr 26Jul 26Oct 26TLRYHigh $17.00Median $4.50Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
3 Buy7 Hold0 Sell
Low $4.00Median $4.50High $17.00

The green dot is the last close — the median target sits +43.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Oct 2026Canaccord GenuityMaintainsHold$4.50 → $4.00
14 July 2026TD CowenMaintainsBuy$7.00 → $5.00
14 July 2026TD CowenMaintainsBuy—
2 Apr 2026Roth CapitalUpgradeBuy—
30 Mar 2026TD CowenMaintainsBuy—
20 Jan 2026Roth CapitalMaintainsNeutral—
25 Aug 2025JefferiesMaintainsBuy—
29 July 2025Zelman & AssocReiteratesNeutral—
9 Apr 2025Piper SandlerMaintainsNeutral—
11 Oct 2024Roth MKMMaintainsNeutral—
27 June 2024Zuanic & AssociatesInitiatesNeutral—
10 Apr 2024CIBCMaintainsNeutral—
1 Sept 2023Roth MKMReiteratesNeutral—
11 Apr 2023TD CowenMaintainsOutperform—
10 Jan 2023Alliance Global PartnersMaintainsNeutral—
2 Nov 2022BernsteinInitiatesMarket Perform—
10 Oct 2022Cantor FitzgeraldMaintainsNeutral—
30 Sept 2022BarclaysMaintainsUnderweight—
2 Aug 2022Cantor FitzgeraldMaintainsNeutral—
29 July 2022BenchmarkDowngradeSell—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TLRY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TLRY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Tilray Brands, Inc. returned −80.4% against +17.5% for the S&P 500, dividends included.

TLRY vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26TLRYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TLRY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−77.8%
Analysts raising
0
Analysts cutting
1
Fundamentals

Tilray Brands, Inc. (TLRY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.0×

Cheaper than 88% of US stocks

Price / sales
0.5×

Cheaper than 81% of US stocks

Price / book
0.3×

Cheaper than 88% of US stocks

EV / EBITDA
48.6×

Cheaper than 5% of US stocks

Growth & margins
Revenue growth (YoY)
22.7%

Higher than 72% of US stocks

Earnings growth (YoY)
25.5%

Higher than 63% of US stocks

Gross margin
32.1%

Higher than 37% of US stocks

Operating margin
−6.2%

Higher than 26% of US stocks

Net margin
−17.1%

Higher than 16% of US stocks

Returns & dividend
Return on equity
−9.4%

Higher than 36% of US stocks

Return on assets
−1.6%

Higher than 38% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Tilray Brands, Inc. (TLRY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tilray Brands, Inc. has a market value of $483.3M and an enterprise value of $616.8M.

  • Revenue in the twelve months to 31 May 2026: $915.5M. The latest quarter grew 22.7% year on year.

  • Net income over the same four quarters: −$105.2M, a −11.5% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.08.

  • Free cash flow in the twelve months to 31 May 2026: −$102.1M.

  • Shares outstanding: 131.1M.

  • Trailing P/E: −3.0×; forward P/E: 19.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Tilray Brands, Inc. employs 3,595 people — $255K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 May 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

TLRY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
TLRYTilray Brands, Inc.$483.3M
16
EOLSEvolus, Inc.$469.7M
90
KMDAKamada Ltd.$473.9M
—
TKNOAlpha Teknova, Inc.$417.7M
96
CGCCanopy Growth Corp.$373.7M
—
AQSTAquestive Therapeutics, Inc.$578.6M
53
IRWDIronwood Pharmaceuticals, Inc.$587.0M
100

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tilray Brands, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TLRY news & analysis

Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets

GlobeNewsWire · 13 Oct 2026positive

Tilray Medical said Portugal’s INFARMED approved its EU-GMP-certified Cantanhede facility to conduct microbiological and chemical/physical quality testing in-house. The company said the approval gives it greater control over testing and supports faster product release for regulated international markets.

Why it matters — The approval strengthens a Tilray facility’s role in quality testing and medical cannabis supply for regulated global markets.

BrewDog Acquisition Boosts Tilray's Q1 Performance

Seeking Alpha · 13 Oct 2026neutral

Tilray reported Q1-2027 results with revenue from its BrewDog operations increasing while cannabis revenue decreased. It also reported a net loss and negative free cash flow, and said its beer assets and international cannabis operations are expected to drive growth.

Why it matters — TLRY watchers may note the contrasting performance of its beer and cannabis businesses alongside the reported loss and negative free cash flow.

Tilray Q1: Not Looking Good, Remains A 'Hold'

Seeking Alpha · 12 Oct 2026negative

Tilray reported fiscal Q1 revenue below estimates despite record-sales messaging from management. Growth came solely from the BrewDog acquisition, while core cannabis sales fell 13%, adjusted results swung to a loss, cash burn rose to $23.4 million, and shares outstanding increased more than 31% year over year.

Why it matters — The results highlight pressure on Tilray’s core cannabis business and profitability, alongside increased cash use and share dilution.

3 Huge Red Flags From Tilray's Q1 Earnings Report

The Motley Fool · 12 Oct 2026negative

The Motley Fool highlights continued cash burn as a major issue in Tilray’s Q1 earnings report. It notes that acquisitions may support top-line growth while also contributing to significantly higher expenses.

Why it matters — Tilray watchers may care about the reported cash burn and the expense implications of the company’s acquisition-led growth.

Canopy Growth vs. Tilray Brands: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · 10 Oct 2026neutral

The Motley Fool compares Canopy Growth and Tilray Brands, noting Canopy's focus on medical and adult-use markets and its Canopy USA expansion strategy. It highlights Tilray's diversified revenue from craft beer and beverages alongside global cannabis operations.

Why it matters — The comparison draws attention to the breadth of Tilray's revenue sources as a point of distinction for TLRY watchers.

FAQ

Frequently asked questions about TLRY stock

What is the TLRY stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Tilray Brands, Inc. have a median 12-month price target of $4.5, with estimates ranging from $4 to $17. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TLRY stock a buy right now?

Of the 10 analysts covering Tilray Brands, Inc., 3 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tilray Brands, Inc. 16 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TLRY?

As at 14 Oct 2026, Tilray Brands, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (95 of 100).

Will TLRY stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +43.3% from the last close, and Ticker Nerd's factor model ranks Tilray Brands, Inc. 16 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TLRY stock forecast for 2030?

No analyst covering Tilray Brands, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TLRY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $17 over the next 12 months.

How has TLRY stock performed over the past year?

Tilray Brands, Inc. returned -80.4% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tilray Brands, Inc. do?

Tilray Brands Inc. is a global lifestyle consumer products company focused on cannabis, beverage alcohol, wellness, and distribution.

What is the latest news on TLRY?

The most recent item we track (GlobeNewsWire, 13 Oct 2026): "Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets". Tilray Medical said Portugal’s INFARMED approved its EU-GMP-certified Cantanhede facility to conduct microbiological and chemical/physical quality testing in-house. The company said the approval gives it greater control over testing and supports faster product release for regulated international markets.

Company

About Tilray Brands, Inc.

Tilray Brands Inc. is a global lifestyle consumer products company focused on cannabis, beverage alcohol, wellness, and distribution. Tilray Brands develops, cultivates, processes, and markets medical and adult-use cannabis products, while also offering hemp-based wellness goods, pharmaceutical distribution services, and a portfolio of craft beverages and spirits. The company serves a broad customer base that includes retailers, wholesalers, patients, healthcare professionals, and consumers across multiple international markets. Its business is organized around four main areas: Cannabis, Beverage, Distribution, and Wellness, allowing it to operate across regulated and consumer-focused categories. Tilray Brands Inc. plays a notable role in the evolving consumer products landscape by combining plant-based wellness offerings with beverage and branded goods under one diversified platform.

CEO Mr. Irwin David Simon · 3,595 employees · Canada · https://www.tilray.com